Suppr超能文献

急性心肌梗死期间的细胞相纤维蛋白溶解和冠状动脉再灌注:一项接受静脉注射链激酶-甲基泼尼松龙治疗患者的研究

Cellular-phase fibrinolysis and coronary reperfusion during acute myocardial infarction: a study in patients receiving intravenous streptokinase-methylprednisolone therapy.

作者信息

Langleben D, Moroz L A, Schlesinger R D

机构信息

Department of Medicine, Lady Davis Research Institute, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.

出版信息

Thromb Res. 1990 Jul 15;59(2):247-58. doi: 10.1016/0049-3848(90)90128-y.

Abstract

Activation of plasma plasminogen to plasmin is the objective of current strategies for thrombolytic therapy. Although thrombolytic activity in blood involves a large cellular component as well as that in plasma, the contribution of this cellular phase to clinical thrombolysis has not been examined. Using a 125I-fibrin test tube assay, we determined blood, plasma and calculated cellular phase fibrinolytic activities in 39 patients with acute myocardial infarction before, immediately after, and at 2 hours after therapy with an intravenous streptokinase-methylprednisolone regimen. By coronary angiography and time to peak creatine phosphokinase levels, 32 patients had coronary reperfusion and 7 did not. Before streptokinase therapy, cellular phase activity of patients who reperfused was more than 2-fold greater than that of patients who did not reperfuse (p less than 0.001), while plasma activities were identical, suggesting that intrinsic cellular phase activity may be a determinant of the success of subsequent thrombolytic therapy. In both groups, in addition to the expected (and similar) increases in plasma activity, cellular phase activity increased when compared with pre-treatment values (+96% to +248%; p less than 0.001), with accompanying increase in blood granulocyte count (+23% to +65%), indicating that blood cells, as well as plasma, are major contributors to streptokinase-mediated fibrinolysis. Cellular phase stimulation was reproduced in a patient receiving streptokinase without methylprednisolone, and by addition of streptokinase to normal blood in vitro, indicating that streptokinase alone could account for these effects. Increased cellular phase activity in patients who reperfused after streptokinase was similar to that in those who did not reperfuse, when pre-treatment values were considered. These findings indicate that initial cellular phase activity in blood may determine subsequent fibrinolytic response, and that there is a significant cellular phase component to the fibrinolytic response to streptokinase, probably mediated by increased numbers of blood neutrophils, with a possible contribution from increased activity of individual neutrophils.

摘要

将血浆纤溶酶原激活为纤溶酶是当前溶栓治疗策略的目标。尽管血液中的溶栓活性涉及大量细胞成分以及血浆中的成分,但该细胞阶段对临床溶栓的贡献尚未得到研究。使用125I-纤维蛋白试管分析法,我们测定了39例急性心肌梗死患者在静脉注射链激酶-甲基泼尼松龙治疗前、治疗后即刻及治疗后2小时的血液、血浆纤溶活性,并计算了细胞阶段纤溶活性。通过冠状动脉造影和肌酸磷酸激酶峰值水平出现的时间,32例患者实现了冠状动脉再灌注,7例未实现。在链激酶治疗前,实现再灌注的患者的细胞阶段活性比未实现再灌注的患者高2倍多(p<0.001),而血浆活性相同,这表明内在细胞阶段活性可能是后续溶栓治疗成功的一个决定因素。在两组中,除了血浆活性出现预期的(且相似的)增加外,与治疗前值相比,细胞阶段活性也增加了(+96%至+248%;p<0.001),同时血液粒细胞计数增加(+23%至+65%),这表明血细胞以及血浆是链激酶介导的纤溶的主要贡献者。在一名接受链激酶但未接受甲基泼尼松龙治疗的患者中,以及通过在体外向正常血液中添加链激酶,再现了细胞阶段刺激,这表明仅链激酶就能解释这些效应。考虑治疗前值时,链激酶治疗后实现再灌注的患者的细胞阶段活性增加与未实现再灌注的患者相似。这些发现表明,血液中初始细胞阶段活性可能决定后续纤溶反应,并且对链激酶的纤溶反应存在显著的细胞阶段成分,可能由血液中性粒细胞数量增加介导,单个中性粒细胞活性增加可能也有贡献。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验